These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 90Y Liver Radioembolization Imaging Using Amplitude-Based Gated PET/CT. Osborne DR; Acuff S; Neveu M; Kaman A; Syed M; Fu Y Clin Nucl Med; 2017 May; 42(5):373-374. PubMed ID: 28240669 [TBL] [Abstract][Full Text] [Related]
5. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases. Kousik V; Promila P; Verma R; Gupta A Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180 [TBL] [Abstract][Full Text] [Related]
6. PET optimization for improved assessment and accurate quantification of 90Y-microsphere biodistribution after radioembolization. Martí-Climent JM; Prieto E; Elosúa C; Rodríguez-Fraile M; Domínguez-Prado I; Vigil C; García-Velloso MJ; Arbizu J; Peñuelas I; Richter JA Med Phys; 2014 Sep; 41(9):092503. PubMed ID: 25186412 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of post-Yttrium 90 radioembolization therapy 18F-fluorodeoxyglucose positron emission tomography in patients with liver tumors. Obrzut S; McCammack K; Badran KW; Balistreri A; Ou E; Nguyen BJ; Hoh CK; Rose SC Clin Imaging; 2017; 42():43-49. PubMed ID: 27875761 [TBL] [Abstract][Full Text] [Related]
8. 90Y microsphere therapy: does 90Y PET/CT imaging obviate the need for 90Y Bremsstrahlung SPECT/CT imaging? Zade AA; Rangarajan V; Purandare NC; Shah SA; Agrawal AR; Kulkarni SS; Shetty N Nucl Med Commun; 2013 Nov; 34(11):1090-6. PubMed ID: 23942324 [TBL] [Abstract][Full Text] [Related]
9. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors. Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830 [TBL] [Abstract][Full Text] [Related]
10. Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. Elschot M; Vermolen BJ; Lam MG; de Keizer B; van den Bosch MA; de Jong HW PLoS One; 2013; 8(2):e55742. PubMed ID: 23405207 [TBL] [Abstract][Full Text] [Related]
11. Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer. Yue J; Mauxion T; Reyes DK; Lodge MA; Hobbs RF; Rong X; Dong Y; Herman JM; Wahl RL; Geschwind JH; Frey EC Med Phys; 2016 Oct; 43(10):5779. PubMed ID: 27782730 [TBL] [Abstract][Full Text] [Related]
12. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT. Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581 [TBL] [Abstract][Full Text] [Related]
13. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133 [TBL] [Abstract][Full Text] [Related]
14. 90Yttrium PET/MR-based dosimetry after liver radioembolization (SIRT). Wissmeyer M; Delattre BM; Zaidi H; Terraz S; Ratib O Clin Nucl Med; 2015 Apr; 40(4):355-7. PubMed ID: 25674869 [TBL] [Abstract][Full Text] [Related]
15. Comparison of PMT-based TF64 and SiPM-based Vereos PET/CT systems for Trotta N; Collette B; Mathey C; Vierasu I; Bucalau AM; Verset G; Moreno-Reyes R; Goldman S Med Phys; 2022 Dec; 49(12):7567-7582. PubMed ID: 35894818 [TBL] [Abstract][Full Text] [Related]
16. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557 [TBL] [Abstract][Full Text] [Related]
17. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison. Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346 [TBL] [Abstract][Full Text] [Related]
18. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma. Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous Time-of-Flight PET/MR Identifies the Hepatic 90Y-Resin Distribution After Radioembolization. Ting CH; Lin KH; Chiu CH; Lee RC; Huang WS Clin Nucl Med; 2020 Feb; 45(2):e92-e93. PubMed ID: 31876809 [TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography/CT after yttrium-90 radioembolization: current and future applications. Gates VL; Salem R; Lewandowski RJ J Vasc Interv Radiol; 2013 Aug; 24(8):1153-5. PubMed ID: 23885913 [No Abstract] [Full Text] [Related] [Next] [New Search]